Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

A woman diagnosed with a rare disease in college is now a researcher working to help others navigate their diagnosis through nutrition science.

The goal of this retrospective study was to assess the diagnostic value and clinical characteristics of painful tonic spasm (PTS) in patients with neuromyelitis optica (NMO). At 2 referral hospitals, ...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

"Multi-center randomized controlled trials with large samples will further confirm the association between vitamin D and NMOSD. It may be necessary for doctors to assess the vitamin D levels of ...

Other symptoms in NMOSD occur in CNS areas besides the optic nerve and spinal cord, including intractable nausea, vomiting, and intractable hiccups in area postrema syndrome (APS, a specific brainstem ...

Please provide your email address to receive an email when new articles are posted on . There is limited information on cytokine levels in neromyelitis optica spectrum disorder. Cytokine levels in ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.